Antibodies to NGAL for Detection of Cancer and Kidney Damage

Published date: March 14, 2017

Technology description

Neutrophil gelatinase-associated lipocalin (NGAL) is a recently discovered cytokine. Because many types of cells produce NGAL in response to injury, it provides a biomarker for several chronic conditions. NGAL can be used in a diagnostic assay to detect certain types of cancer cells. It serves as a strong indicator of kidney damage, and may be useful to monitor other chronic conditions as well. UW-Madison researchers have developed purified antibodies to NGAL. These unique antibodies can be used in immunoassays for the diagnosis and prognosis of some types of cancer, renal failure and other diseases.
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in unique antibodies to neutrophil gelatinase-associated lipocalin (NGAL).

Additional Information

Stoesz S.P., Friedl A., Haag J.D., Lindstrom M.J., Clark G.M., and Gould M.N. 1998. Heterogeneous Expression of the Lipocalin N-gal in Primary Breast Cancers. Int. J. Cancer 79, 565-572.
Stoesz S.P., Friedl A., Haag J.D., Lindstrom M.J., Clark G.M., and Gould M.N. 1998. Heterogeneous Expression of the Lipocalin N-gal in Primary Breast Cancers. Int. J. Cancer 79, 565-572.

Application area

Immunoassays for cancer, kidney damage and other chronic conditions

Advantages

Provides unique antibodies against NGAL

Institution

Wisconsin Alumni Research Foundation

Inventors

Jill Haag
Michael Gould